FDA Top Vaccine Regulator Reinstated Amid Turmoil
TL;DR Summary
The FDA is currently facing turmoil after approving Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy in 2023, which was later linked to three patient deaths from liver failure, leading to a suspension request and a sharp decline in Sarepta's stock value.
Topics:business#drug-approval#duchenne-muscular-dystrophy#fda#rare-diseases#sarepta-therapeutics#world
- America’s drug regulator is in turmoil The Economist
- Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency Reuters
- UCSF doctor reinstated at FDA less than 2 weeks after resigning amid MAGA backlash San Francisco Chronicle
- FDA official returns to agency after Loomer-led ouster CNN
- Top vaccine regulator returns to FDA after recent firing Politico
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 1 min read
Condensed
79%
197 → 42 words
Want the full story? Read the original article
Read on The Economist